Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The role of palliative irradiation was analysed in 55 patients with liver metastases from colorectal (n = 35), breast (n = 10) and lung cancer (n = 10), treated between January 1982 and June 1992 with irradiation doses more than 10 Gy. In 47 patients irradiation alone was done. The great majority of patients were treated because of pain (n = 21) or cholestasis (n = 22). In 29 patients the disease involved not only the liver, but was disseminated. A mean dose of 23.8 Gy was delivered, with daily fractions of 1.5 (n = 30), 1.8 (n = 1) or 2 Gy (n = 16). Complete and near complete pain relief was obtained in six (28.6%) and nine (42.9%) patients. Normalized and near normalized values of bilirubin serum levels were obtained in five (22.7%) and seven (31.9%) patients. As well relief of pain as normalisation of cholestasis were significantly correlated with the irradiation doses applied. Median survival was 36.5 days for patients with lung cancer, 70.5 and 73 days for patients with breast and colorectal cancer. Irradiation doses given (10 to 18 Gy vs. 19 to 28 Gy vs. 29 to 48 Gy) and the status of disease (liver only vs. disseminated) were significantly correlated to prognosis (p = 0.00001, p = 0.0007). Patients of the high-dose group or patients with liver metastases alone revealed a median survival of 174 or 175 days. Since May 1991 simultaneous radio-chemotherapy, with the systemic application of leukovorine and 5-FU, was performed in eight patients with colorectal cancer. After performing a three-dimensional radiotherapy planning, which enclosed the whole liver inside the target volume, a mean dose of 29.4 Gy, with daily single fractions of 1.5 Gy was delivered. The follow-up, done with CT or NMR revealed in seven patients a progression free interval of three to 8.5 (5.5) months. After a median follow-up of 221 days the median survival was 333 days. In the treatment of patients with liver metastases a clear therapeutic selection has to be done according to valid prognostic criteria. In the majority of our patients with clinical symptoms, i.e. pain or cholestasis, irradiation alone was sufficient for palliation of these symptoms. Prognosis is limited because of the disseminated state of disease in 62% of the patients. In a group of patients, suffering from colorectal cancer with good prognostic criteria, the simultaneous application of radiotherapy and systemic chemotherapy was able to increase significantly the survival with minor toxicity.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[The value of radiotherapy for liver metastases]. 768 54

CDDP and 5-FU are time dependent drugs and their increasing effect is expected because of the dual chemical modulation. The low dose continuous infusion of CDDP and 5-FU was applied to the terminal adenocarcinoma patients with the metastatic lesions. One patient was 42 years old lung cancer patient with the metastatic lesions in the liver, the bone, the pericardial space, the underskin, the muscles and the lymph nodes (stage IV). The another patient was 61 years old rectum cancer patient with lung and hepatic metastasis (stage V). Both patients were directly informed of the true name of the disease and the poor curability from the physician in charge. The physician promised them to take the home therapy as much as possible in order to pursuit their own life value at home. The lung cancer patient got the radiotherapy first to remove the bone pain and the rectum cancer patient was operated to make the stoma to avoid the obstructive ileus beforehand. After the therapy, two patients took the low dose continuous infusion of CDDP and 5-FU. In both cases, the abdominal symptoms such as nausea and vomiting due to the therapy were not recognized and the hematopoietic disorders and the renal failure were slight, so they could get the therapy continuously for very long. The lung cancer patient lived 9 months after the diagnosis and the low dose infusion chemotherapy has continued for 7 months, the home stay for 4 months. The rectum cancer patient lived 13 months and the same chemotherapy has continued for 12.5 months, the home stay for 7.5 months. The low dose continuous infusion therapy of CDDP and 5-FU is an effective treatment for terminal cancer patients as one of the home therapies from the point of the QOL (quality of life).
 ...
PMID:[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home]. 780 48

Two adenocarcinoma cell lines were established from metastatic lymph node of lung cancer patients. The cell lines were named NUTLC-1 and NUTLC-3. They were found to have the following biological characterization and sensitivity to anticancer agents by comparison with clinical effect of the drugs on each donor patient: 1) By chromosomal analysis, the tumor cells of two cell lines were human-origin cells. Number of chromosomes of these cell lines ranged from 67 to 77 in NUTLC-1 cells and from 61 to 66 in NUTLC-3 cells, with the modal numbers of 73 and 64, respectively. 2) The tumor cells of the two cell lines were heterotransplanted subcutaneously into nude mice, but, no natural distant metastasis was observed 2 months after transplantation. 3) Sensitivity to anticancer agents on NUTLC-1 and NUTLC-3 cells differed individually according to methylthiazol tetrazorium (bromide) (MTT) colorimetric assay. NUTLC-1 cells were sensitive to Mitomycin C (MMC) and Adriamycin (ADM), and insensitive to Cisplatinum (CDDP), 5-Fluorouracil (5-FU) and Etoposide (VP-16). Antitumor effect of CDDP and 5-FU on recurrent tumor of donor patient was not observed clinically. NUTLC-3 cells were sensitive to CDDP, MMC and ADM, and insensitive to 5-FU and VP-16. Sensitivity to CDDP and MMC on NUTLC-3 cells also correlated to clinical effect of the drugs on the donor patient. From these results, it appears that these new cell lines are useful materials for studies on lung cancer.
 ...
PMID:Characteristics of the two newly established cell lines of human pulmonary adenocarcinoma and their sensitivity to anticancer agents. 802 20

Combined treatment of UFT with cisplatin (CDDP) achieved remarkable elongation of survival time of BDF1 mice, which were intravenously transplanted with Lewis lung carcinoma (LLC). Three cycles of weekly iv administration of CDDP and vindesine (VDS), and daily oral administration of UFT were scheduled. Combination UFT (18 mg/kg/day) with CDDP (6.0 mg/kg/day) yielded tumor-free survivors in all of the treated animals with slight body weight loss. Its efficacy was superior to that of the combination of CDDP with VDS. Supra-additive cytotoxic activity against LLC cells was observed by Isobologram method on the schedule of the exposure to 5-fluorouracil preceding the exposure to CDDP. Additive effect was observed by the reversed schedule of the treatment. Using human non-small-cell lung cancer (NSCLC) cell lines which derived from histologically different type, additive or greater additive sensitivity to both of the sequential treatment schedules with 5-FU and CDDP was observed. These results suggest that the combination chemotherapy of UFT with CDDP for lung cancer may show high antitumor efficacy with low toxicity in a clinical setting.
 ...
PMID:[Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer]. 821 Feb 49

Nebulisation chemotherapy, a chemotherapeutic method for the treatment of lung cancer that involves the administration of anticancer agents through the inhalation of nebulised aerosols, has been found to be highly effective (Tatsumura et al., 1983a,b). We confirmed that 5-FU administered by this method accumulates in the trachea, bronchi and regional lymph nodes of patients treated before surgery, along with 5-FU metabolites, FUR and FUdR, indicating that 5-FU is directly incorporated and metabolised in the respiratory tract. Parallel result were obtained using mongrel dogs. The 5-FU levels in other organs, such as the heart and liver, were found to be extremely low. Only a trace of 5-FU was found in the serum of both the patients and the dogs. We further investigated the anti-tumour effect of this therapy in ten selected patients and observed a satisfactory anti-tumour response of 60.0%. These results, along with our previous finding that the retention time of isotope tracers inhaled as aerosol is considerably longer in tumour tissues than in normal parts (Tatsumura et al., 1983a) explain the high antitumour action of this therapy and the absence of adverse effects of administered 5-FU.
 ...
PMID:Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. 826 Mar 66

CDDP, commonly used in cancer chemotherapy, behaves as not only effector but also modulator of 5-FU when combined with 5-FU and the derivatives. Therefore, the antitumor activity of combination treatment of BOF-A2, a new 5-fluorouracil derivative, with CDDP was evaluated with two human lung cancers (H-74 and LC-376) xenografted in nude mice. BOF-A2 was orally administered at 30 mg/kg (MTD) or 15 mg/kg (1/2 MTD) 3 times a week totally twelve times, and CDDP was administrated interperitoneally at 5 mg/kg (MTD) or 2.5 mg/kg (1/2 MTD) once a week totally 4 times. The antitumor effect of combination of two drugs at the 1/2 MTD was effective to H-74 and markedly effective to LC-376, and the effect was more remarkable than each drug administered individually at the 1/2 MTD, and the combination effect was additive. The effect by the combination was not synergistic but showed a similar activity compared with single drug given individually at the MTD. Moreover, the side effect of combination of the 1/2 MTD was less than group given MTD of CDDP in terms of body weight loss. These data suggests a clinical usefulness of combination BOF-A2 with CDDP against lung cancer.
 ...
PMID:[Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice]. 838 36

We designed our study to evaluate the safety and efficacy of simultaneous chemoradiation therapy in an accelerated, twice-a-day schedule to improve local control and survival in advanced lung cancer patients. Forty-one patients were entered into the study. Twenty-three had stage IIIB and 18 had stage IIIA disease. They received cisplatin 30 mg/m2, VP-16 80 mg/m2, and 5-Fluorouracil (5-FU) 900 mg/m2 in iv infusion. Radiation therapy consisted of 2G twice a day for 5 days, followed by a 2-week rest. This cycle was repeated 3 times. Patients were evaluated for surgical resection after the second cycle. Acute toxicity was acceptable: 3 patients expired (1 congestive heart failure, 1 sepsis, 1 pulmonary embolism). The 1-year actuarial survival was 60.3%; the 2-year actuarial survival was 55.3%. Our results show that this regimen is well tolerated and that the 2-year actuarial survival appears to be comparable to that reported in the literature.
 ...
PMID:Simultaneous chemoradiation in advanced non-small cell lung cancer. 838 89

The authors previously reported the advantages of a collagen gel embedded culture system for chemosensitivity tests for cancer. In this report, the chemosensitivities of surgically resected specimens were evaluated by the collagen gel embedded culture system and compared with the DNA ploidy pattern, measured by flow cytometry. The chemosensitivity and DNA ploidy pattern were determined in 11 patients with lung cancer, 8 with gastric cancer and 46 with colorectal cancer. Anticancer agents were MMC and CDDP at Cmax for one hour of exposure, and 5-FU, VDS, VP-16 and ADM at one tenth the Cmax for 24 hours of exposure. Results were compared with those of DNA histogram. In eight lung cancers which were demonstrated to be sensitive by the collagen gel system, 5 showed DNA aneuploidy (DA) and 3 DNA diploidy (DD). Seven cases (87.5%) of gastric cancer were demonstrated to be sensitive with the collagen gel system. Two of them showed DA and five DD. On the other hand, 19 cases (41.3%) of colorectal cancer were found to be sensitive, and 7 of them showed DA and twelve DD. Lung cancer and gastric cancer exhibiting aneuploidy demonstrated sensitivity with the collagen gel system, but the rate of sensitivity was only 28% in colorectal cancer, and even aneuploidy cases showed a low sensitivity.
 ...
PMID:[Evaluation of chemosensitivity test for cancer using the collagen gel embedded culture system--DNA ploidy pattern and chemosensitivity]. 848 93

Fourteen cases of metastatic brain tumors from lung cancer underwent biochemical modulation chemotherapy with daily administration of small doses of CDDP (5 or 10 mg/day) and continuous infusion of 5-FU (300 mg/day) for three tow six weeks. All patients with metastatic brain tumors also underwent a total of 30 Gy of whole brain irradiation therapy. Of eleven patients who had metastatic brain tumors when chemotherapy started, complete and partial responses were shown in two patients each (36% response rate). Moreover, only four of twelve patients with extracranial lesions responded (33% response rate). Abnormal levels of tumor marker were improved in only three of 10 evaluable patients (30% response rate). Side effects of this chemotherapy included various WHO grades of bone marrow suppression as well as nausea and vomiting in 13 of 14 patients. Loss of appetite persisted for two months. Parkinsonism was also noted in three patients as an additional side effect. Mean survival time was 9.4 months, while 4 patients survived longer than one year. Data showing a low response rate, persistent loss of appetite and longer admission period were considered less favorable than those of other chemotherapeutic regimens.
 ...
PMID:[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. 905 28

A total of 55 patients with measurable colorectal metastatic carcinoma were studied to evaluate the impact on toxicity, response, and survival of protracted venous infusion (PVI) 5-FU 200 mg/m2 per day with Cis-DDP 80 mg/m2 or carboplatin 300 mg/m2 every 3 weeks, 1-hour infusion. Patients received continuous uninterrupted therapy until there were signs or symptoms of toxicity. Both 5-FU and cisplatin were withheld when patients experienced grade II stomatitis and diarrhea, severe nausea or vomiting not controlled by standard antiemetic therapy, and clinically significant hand-foot syndrome. The toxicity was neurological (20% grade 2 and 3) hematological (13% grade 2) and dermatological (11% grade 2). The overall response (CR+PR) was 24% with a median survival of 13 months. The results of our study show that there is no improvement in response rate, response duration or survival compared with historical trials. However, this study does confirm the valuable palliative role of the protracted 5-FU infusion treatment. Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy. The management of nonmetastatic primary disease in surgical, with adjuvant chemotherapy for those at high risk of relapse. However, for those with metastatic disease at diagnosis or recurrent disease after resection, cytotoxic chemotherapy is the treatment of choice and fluorouracil (5-FU) is the most active cytotoxic agent in this disease, with a response rate of approximately 20%. Efforts to improve the response rate have focused on the use of agents to modulate 5 FU. The Southwestern Oncology Group (SWOG) study reported by Leichman et al. (1) and a study from the United Kingdom by Hill et al. (2) compared conventional FU to modulated FU and found no improvement in response rate or survival. In the SWOG study, two different schedules of bolus FU and LV were compared with bolus FU alone and to continuous infusion FU administered alone or modulated by LV or PALA. In this study, the results obtained with bolus FU were superior to most of the studies in the literature: The response rate was 26%, and the median survival was 14 months. The high- and low-dose LV and FU groups showed response rates and survival similar to bolus FU alone. However, in 12 previously reported randomized studies comparing FU and LV or FU alone, nine reported that the combination of FU and LV produced significant increases in response rates and two reported significant increase in survival (3, 4). Many of these trials used the dose schedules reported in the SWOG trial. Protracted venous infusion (PVI) 5-FU has been shown to have superior efficacy with less toxicity in colorectal cancer when compared to bolus 5-FU and synergy between cisplatin and 5-FU has been demonstrated in vitro. Consequently, we have investigated the efficacy of the combination of bolus cis or carboplatin and PVI 5 FU in 55 patients with advanced colorectal cancer using survival, response rate, symptomatic response, and toxicity as study endpoints.
 ...
PMID:First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. 922 28


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>